Cyxone to research additional autoimmune conditions
In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.Work on developing T20K for multiple sclerosis has indicated that cyclotides have excellent drug properties. The cellular processes on which T20K has an effect have been found by independent researchers to also be significant for autoimmune conditions. The inflammatory bowel disease study is part of Cyxone's strategy to investigate whether cyclotides under existing patents should be